{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:59:05Z","timestamp":1789660745196,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejca.2013.03.018","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T20:01:05Z","timestamp":1367956865000},"page":"2384-2391","source":"Crossref","is-referenced-by-count":64,"title":["Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children\u2019s Oncology Group"],"prefix":"10.1016","volume":"49","author":[{"given":"Robert E.","family":"Goldsby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doojduen","family":"Villaluna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lor Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gorlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neyssa","family":"Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2013.03.018_b0005","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1023\/A:1008361612767","article-title":"A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI)","volume":"10","author":"Voute","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.018_b0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cncr.20317","article-title":"A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis","volume":"101","author":"Patel","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.018_b0015","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.018_b0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.1993.11.3.449","article-title":"Osteogenic sarcoma with clinically detectable metastasis at initial presentation","volume":"11","author":"Meyers","year":"1993","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.018_b0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.2001.19.1.171","article-title":"Carboplatin\/ifosfamide window therapy for osteosarcoma: results of the St Jude Children\u2019s Research Hospital OS-91 trial","volume":"19","author":"Meyer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2013.03.018_b0030","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.1998.16.11.3641","article-title":"Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study","volume":"16","author":"Harris","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0035","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.20.2.426","article-title":"Phase II\/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial","volume":"20","author":"Goorin","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0040","first-page":"339","article-title":"Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide","volume":"7","author":"Bacci","year":"2000","journal-title":"Oncol Rep"},{"issue":"15","key":"10.1016\/j.ejca.2013.03.018_b0045","first-page":"5442","article-title":"Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary","volume":"9","author":"Gorlick","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.018_b0050","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.23775","article-title":"Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database","volume":"113","author":"Hatoum","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2013.03.018_b0055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2013.03.018_b0060","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2013.03.018_b0065","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2013.03.018_b0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"12 Pt 1","key":"10.1016\/j.ejca.2013.03.018_b0075","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.25051","article-title":"Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model","volume":"127","author":"Labrinidis","year":"2010","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.018_b0085","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2013.03.018_b0090","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2013.03.018_b0095","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00001813-200106000-00007","article-title":"The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro","volume":"12","author":"Sonnemann","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0100","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S8756-3282(03)00223-0","article-title":"Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis","volume":"33","author":"Evdokiou","year":"2003","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjc.6603548","article-title":"Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma","volume":"96","author":"Horie","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.018_b0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"issue":"34","key":"10.1016\/j.ejca.2013.03.018_b0115","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2013.03.018_b0120","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejca.2013.03.018_b0125","series-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"2002"},{"issue":"8","key":"10.1016\/j.ejca.2013.03.018_b0130","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/cncr.22553","article-title":"Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children\u2019s Cancer Group (CCG) 7943","volume":"109","author":"Seibel","year":"2007","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.ejca.2013.03.018_b0135","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children\u2019s Oncology Group","volume":"115","author":"Chou","year":"2009","journal-title":"Cancer"},{"issue":"2 Suppl. 6","key":"10.1016\/j.ejca.2013.03.018_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(01)90262-3","article-title":"Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2013.03.018_b0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/pbc.22821","article-title":"A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent\/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study","volume":"57","author":"Russell","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2013.03.018_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2013.03.018_b0155","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ejca.2013.03.018_b0160","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.018_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.orthres.2004.06.004","article-title":"Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial","volume":"23","author":"Wilkinson","year":"2005","journal-title":"J Orthop Res"},{"issue":"5","key":"10.1016\/j.ejca.2013.03.018_b0170","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-04-2463","article-title":"An expression signature classifies chemotherapy-resistant pediatric osteosarcoma","volume":"65","author":"Mintz","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2013.03.018_b0175","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.25744","article-title":"Addition of pamidronate to chemotherapy for the treatment of osteosarcoma","volume":"117","author":"Meyers","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2013.03.018_b0180","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/pbc.22681","article-title":"The use of zoledronic acid in pediatric cancer patients","volume":"56","author":"August","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2013.03.018_b0185","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/jbmr.453","article-title":"Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient","volume":"26","author":"Battaglia","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.ejca.2013.03.018_b0190","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00223-010-9366-z","article-title":"Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats","volume":"86","author":"Hiraga","year":"2010","journal-title":"Calcif Tissue Int"},{"issue":"22","key":"10.1016\/j.ejca.2013.03.018_b0195","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.03.018_b0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.03.018_b0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T08:00:49Z","timestamp":1715328049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0959804913002219"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.03.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}